| __timestamp | BioMarin Pharmaceutical Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 520990000000 |
| Thursday, January 1, 2015 | 152008000 | 535405000000 |
| Friday, January 1, 2016 | 209620000 | 558755000000 |
| Sunday, January 1, 2017 | 241786000 | 495921000000 |
| Monday, January 1, 2018 | 315264000 | 659690000000 |
| Tuesday, January 1, 2019 | 359466000 | 1089764000000 |
| Wednesday, January 1, 2020 | 524272000 | 994308000000 |
| Friday, January 1, 2021 | 470515000 | 1106846000000 |
| Saturday, January 1, 2022 | 483669000 | 1244072000000 |
| Sunday, January 1, 2023 | 577065000 | 1431505000000 |
| Monday, January 1, 2024 | 1431505000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for assessing a company's financial health. This analysis focuses on two major players: Takeda Pharmaceutical Company Limited and BioMarin Pharmaceutical Inc., from 2014 to 2023.
Takeda, a Japanese multinational, has shown a robust upward trend in its cost of revenue, peaking at approximately 1.43 trillion in 2023. This represents a staggering 175% increase from 2014, reflecting its aggressive expansion and strategic acquisitions.
BioMarin, a leader in rare disease therapies, has also experienced growth, with its cost of revenue rising by 345% over the same period. Despite its smaller scale compared to Takeda, BioMarin's consistent increase highlights its expanding market presence.
Both companies demonstrate the dynamic nature of the pharmaceutical sector, with Takeda's scale and BioMarin's niche focus offering unique insights into industry strategies.
Analyzing Cost of Revenue: Sanofi and BioMarin Pharmaceutical Inc.
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited
Analyzing Cost of Revenue: Takeda Pharmaceutical Company Limited and Cytokinetics, Incorporated
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs Grifols, S.A.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Telix Pharmaceuticals Limited
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc.'s Expenses
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.